Navigation Links
AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
Date:1/28/2010

LONDON, January 28 /PRNewswire-FirstCall/ -- Pharmaceutical group AstraZeneca announced it's Q4 and full-year results today with CEO David Brennan saying in a video interview on http://www.cantos.com that cost control and restructuring had helped deliver a revenue line above company expectations.

In the video Mr Brennan looks at the results and the drivers behind a 23% rise in core operating profit and, significantly, a 12% dividend increase. He discusses the rationale behind the "significant" R&D changes that the company is implementing as well as progress on the ongoing restructuring programme and where he sees future growth and opportunities coming from.

While he says the next five years will be challenging, the long-term future looks strong.

"We're entering a period of time where we are launching new products and we're excited about them, but it's going to take a few years for those products to get up to the revenue contribution that we need that will balance some of the patent expirations."

The interview and transcript are available now on http://www.cantos.com/company/astrazeneca.

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email amanda.alexander@cantos.com or phone +44-207-936-1352.

SOURCE AstraZeneca Plc


'/>"/>
SOURCE AstraZeneca Plc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease
2. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
3. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
4. BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
5. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
6. AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
7. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
8. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
9. AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
10. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
11. Melior Enters Research Collaboration with AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... York , May 4, 2016 ... Transparency Market Research "Metabolomics Market - Global Industry Analysis, ... the metabolomics market is anticipated to expand at a ... USD 2,494.8 million by 2024. Metabolomics is ... metabolites, within cells, biofluids, tissues or organisms. Together, these ...
(Date:5/3/2016)... ... 2016 , ... In a list published by the Boston Business Journal, ... companies; a small percentage of the state's 615,000+ small businesses. The list examined companies ... revenue from 2012 to 2015. , As this award comes on the ...
(Date:5/3/2016)... May 3, 2016 - And ... and Producers of Those Competitor Biologics  - ... Activities and Prospects ,  Who are the ... And what are their sales potentials? Discover, in our ... results, trends, opportunities and revenue forecasting. ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... in mind, the fresh look and added functionality give the agricultural world a ... seen a dynamic shift in agriculture – from precision farming via satellites and ...
Breaking Biology Technology:
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/11/2016)... HANOVER, Germany , March 11, 2016 ... - Cross reference: Picture is available at AP Images ( ... scanner from DERMALOG will be used to produce the new refugee ... of other biometric innovations, at CeBIT in Hanover ... LF10 scanner from DERMALOG will be used to produce the new ...
(Date:3/9/2016)... , March 9, 2016 ... government identified that more than 23,000 public service employees ... had been receiving their salary unlawfully.    --> ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ...
Breaking Biology News(10 mins):